Introduction: Although the biology and sites of secretion of PSA are well known, its pharmacokinetics are still unclear. This study analyzes the differences between the clearance of total and free serum PSA following open surgery for BPH and radical prostatectomy. Methods: Free and total PSA were measured in 27 patients submitted to radical prostatectomy for clinically localized prostate cancer (group I) and in 27 patients submitted to open surgery for BPH (group II). In both groups, the clearance of free and total PSA was studied. Results: Group I – the mean half-life was 1.416 ± 0.723 days for free PSA and 2.43 ± 0.688 days for total PSA. After prostate removal, free PSA showed a marked increase. Group II – the mean half-life of free PSA was 2.157 ± 1.792 days and 3.391 ± 2.337 days for total PSA. Conclusions: The increase in free PSA shortly after manipulative procedures of the prostate was higher than the increase in total PSA. Serum clearance of free PSA after eradicative prostatic surgery was related to the indication and type of procedure used.

Stenman UH, Leinonen J, Alftahan H, Rannikko S, Tuhkanen K, Alftahan O: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–226.
Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M, Cockett ATK, Abrahamsson P-A, Lilja H: Serum prostate-specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100–105.
Wood WG, van der Sloot E, Böhle A: The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen α1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787.
Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518–524.
Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187–194.
Froschermaier SE, Pilarsky CP, Wirth MP: Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology 1996;47:525–528.
Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase cancer. N Engl J Med 1991;324:1156.
Semjonow A, Oberpenning F, Surdel W, Weining C, Brandt B, Brandau W, Hertle L: Prostate-specific antigen and radical prostatectomy: Variation after manipulation of the prostate and consecutive elimination half-life of free and total PSA. J Urol 1996;155:697A.
Graves HCB, Wehner N, Stamey TA: Ultrasensitive radioimmunoassay for prostate specific antigen. Clin Chem 1992;38:735.
Haab F, Meulemans A, Boccon-Gibod Li, Dauge MC, Delmas V, Boccon-Gibod L: Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy and radical prostatectomy. Prostate 1995;26:334–338.
Lilja H, Cockett ATK, Abrahamsson PA: Prostate specific antigen predominantly forms a complex with alpha-1-antichymotrypsin in blood. Cancer 1992;70:230–234.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.